Header Logo

Connection

Peter Friedmann to Opioid-Related Disorders

Back to Details
This is a "connection" page, showing publications Peter Friedmann has written about Opioid-Related Disorders.
Peter Friedmann
Connection Strength
18.974
Opioid-Related Disorders
  1. Soares WE, Lewis O, Shrestha S, Stopka TJ, Friedmann PD. "When" matters: Differences in fatal opioid-related overdose events in Massachusetts by time of day, 2019-2023. Drug Alcohol Depend. 2026 Jun 01; 283:113141.
    View in: PubMed
    Score: 0.569
  2. Oser CB, Sprunger JG, Hunt T, Holloway J, Chandler RK, Freisthler B, Balvanz P, Henry BF, Glasgow L, Harris DR, Walsh SL, Aldridge AP, Asman K, Blevins D, Booty MD, Fox AD, Springer SA, Kinnard EN, Knott C, LeBaron PA, Levin FR, Marks KR, McGladrey ML, Nunes EV, Oga EA, Smith MR, Smith MS, Staton M, Stevens-Watkins D, Surratt HL, Walters ST, Zarkin GA, Friedmann PD. The impact of the communities that HEAL intervention on the provision of jail-based medication for opioid use disorder & linkage programs at release: Results from a randomized, wait-list controlled trial. J Subst Use Addict Treat. 2026 Feb; 181:209835.
    View in: PubMed
    Score: 0.556
  3. Friedmann PD, Wilson D, Stopka TJ, Bernson D, Pivovarova E, Ferguson W, Hoskinson RA, Rottapel RE, Bovell-Ammon B, Gaba A, Morgan JR, Senst T, Hayes E, Evans EA. Medications for Opioid Use Disorder in County Jails - Outcomes after Release. N Engl J Med. 2025 Sep 11; 393(10):994-1003.
    View in: PubMed
    Score: 0.549
  4. Pivovarova E, Taxman FS, Boland AK, Andraka-Christou B, De La Cruz BA, Smelson D, Lemon SC, Friedmann PD. Medication for Opioid Use Disorders (MOUD) Providers' Experiences with Recovery Courts: Qualitative Study of Individual and Systemic Factors Impacting Interagency Collaboration. Subst Use Addctn J. 2025 07; 46(3):531-540.
    View in: PubMed
    Score: 0.520
  5. Michener PS, Bianchet E, Fox S, Evans EA, Friedmann PD. "Expected to happen": perspectives on post-release overdose from recently incarcerated people with opioid use disorder. Harm Reduct J. 2024 07 22; 21(1):138.
    View in: PubMed
    Score: 0.507
  6. Michener PS, Evans EA, Ferguson WJ, Friedmann PD. Diffusion of medications for opioid use disorder treatment in jail settings: a convergent mixed methods study of jail staff perspectives. Addict Sci Clin Pract. 2024 02 12; 19(1):10.
    View in: PubMed
    Score: 0.492
  7. Michener PS, Knee A, Wilson D, Boama-Nyarko E, Friedmann PD. Association of random and observed urine drug screening with long-term retention in opioid treatment programs. Drug Alcohol Depend. 2024 02 01; 255:111067.
    View in: PubMed
    Score: 0.487
  8. Evans EA, Pivovarova E, Senthilkumar R, Rottapel RE, Stopka TJ, Santelices C, Ferguson WJ, Friedmann PD. Diversion of medications to treat opioid use disorder: Qualitative findings from formerly incarcerated adults in Massachusetts. Int J Drug Policy. 2023 12; 122:104252.
    View in: PubMed
    Score: 0.484
  9. Pivovarova E, Taxman FS, Boland AK, Smelson DA, Lemon SC, Friedmann PD. Facilitators and barriers to collaboration between drug courts and community-based medication for opioid use disorder providers. J Subst Use Addict Treat. 2023 04; 147:208950.
    View in: PubMed
    Score: 0.456
  10. Matsumoto A, Santelices C, Evans EA, Pivovarova E, Stopka TJ, Ferguson WJ, Friedmann PD. Jail-based reentry programming to support continued treatment with medications for opioid use disorder: Qualitative perspectives and experiences among jail staff in Massachusetts. Int J Drug Policy. 2022 11; 109:103823.
    View in: PubMed
    Score: 0.444
  11. Jawa R, Walley AY, Wilson DJ, Green TC, McKenzie M, Hoskinson R, Bratberg J, Ramsey S, Rich JD, Friedmann PD. Prescribe to Save Lives: Improving Buprenorphine Prescribing Among HIV Clinicians. J Acquir Immune Defic Syndr. 2022 08 15; 90(5):546-552.
    View in: PubMed
    Score: 0.443
  12. Nolte K, Romo E, Stopka TJ, Drew A, Dowd P, Del Toro-Mejias L, Bianchet E, Friedmann PD. "I've been to?more?of my friends'?funerals?than?I've been to my friends' weddings": Witnessing and responding to overdose in rural Northern New England. J Rural Health. 2023 01; 39(1):197-211.
    View in: PubMed
    Score: 0.431
  13. Pivovarova E, Evans EA, Stopka TJ, Santelices C, Ferguson WJ, Friedmann PD. Legislatively mandated implementation of medications for opioid use disorders in jails: A qualitative study of clinical, correctional, and jail administrator perspectives. Drug Alcohol Depend. 2022 05 01; 234:109394.
    View in: PubMed
    Score: 0.430
  14. Evans EA, Pivovarova E, Stopka TJ, Santelices C, Ferguson WJ, Friedmann PD. Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail. J Subst Abuse Treat. 2022 07; 138:108746.
    View in: PubMed
    Score: 0.429
  15. Evans EA, Wilson D, Friedmann PD. Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder. Drug Alcohol Depend. 2022 02 01; 231:109254.
    View in: PubMed
    Score: 0.426
  16. Peacock-Chambers E, Paterno MT, Kiely D, Fioroni T, Byatt N, Friedmann PD. Engagement in perinatal outpatient services among women in recovery from opioid use disorders. Subst Abus. 2021; 42(4):1022-1029.
    View in: PubMed
    Score: 0.403
  17. Pivovarova E, Min HS, Friedmann PD. Impact of extended release naltrexone on health-related quality of life in individuals with legal involvement and opioid use disorders. Subst Abus. 2021; 42(4):618-624.
    View in: PubMed
    Score: 0.387
  18. Peacock-Chambers E, Feinberg E, Senn-McNally M, Clark MC, Jurkowski B, Suchman NE, Byatt N, Friedmann PD. Engagement in Early Intervention Services Among Mothers in Recovery From Opioid Use Disorders. Pediatrics. 2020 02; 145(2).
    View in: PubMed
    Score: 0.372
  19. Abraham AJ, Andrews CM, Harris SJ, Friedmann PD. Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA. Neurotherapeutics. 2020 01; 17(1):55-69.
    View in: PubMed
    Score: 0.370
  20. Paterno MT, Jablonski L, Klepacki A, Friedmann PD. Evaluation of a Nurse-Led Program for Rural Pregnant Women With Opioid Use Disorder to Improve Maternal-Neonatal Outcomes. J Obstet Gynecol Neonatal Nurs. 2019 Sep; 48(5):495-506.
    View in: PubMed
    Score: 0.359
  21. Stopka TJ, Jacque E, Kelso P, Guhn-Knight H, Nolte K, Hoskinson R, Jones A, Harding J, Drew A, VanDonsel A, Friedmann PD. The opioid epidemic in rural northern New England: An approach to epidemiologic, policy, and legal surveillance. Prev Med. 2019 11; 128:105740.
    View in: PubMed
    Score: 0.355
  22. Andrews CM, Abraham AJ, Grogan CM, Westlake MA, Pollack HA, Friedmann PD. Impact of Medicaid Restrictions on Availability of Buprenorphine in Addiction Treatment Programs. Am J Public Health. 2019 03; 109(3):434-436.
    View in: PubMed
    Score: 0.346
  23. Soares WE, Wilson D, Gordon MS, Lee JD, Nunes EV, O'Brien CP, Shroff M, Friedmann PD. Incidence of future arrests in adults involved in the criminal justice system with opioid use disorder receiving extended release naltrexone compared to treatment as usual. Drug Alcohol Depend. 2019 01 01; 194:482-486.
    View in: PubMed
    Score: 0.343
  24. Abraham AJ, Andrews CM, Grogan CM, Pollack HA, D'Aunno T, Humphreys K, Friedmann PD. State-Targeted Funding and Technical Assistance to Increase Access to Medication Treatment for Opioid Use Disorder. Psychiatr Serv. 2018 04 01; 69(4):448-455.
    View in: PubMed
    Score: 0.321
  25. Friedmann PD, Dunn KE, Nunes EV, O'Brien CP. Effectiveness, Implementation and Real-World Experience with Extended-Release Naltrexone (XR-NTX): A Special Issue of JSAT. J Subst Abuse Treat. 2018 02; 85:31-33.
    View in: PubMed
    Score: 0.319
  26. Friedmann PD, Suzuki J. More beds are not the answer: transforming detoxification units into medication induction centers to address the opioid epidemic. Addict Sci Clin Pract. 2017 11 15; 12(1):29.
    View in: PubMed
    Score: 0.319
  27. Soares WE, Wilson D, Rathlev N, Lee JD, Gordon M, Nunes EV, O'Brien CP, Friedmann PD. Healthcare utilization in adults with opioid dependence receiving extended release naltrexone compared to treatment as usual. J Subst Abuse Treat. 2018 02; 85:66-69.
    View in: PubMed
    Score: 0.308
  28. Friedmann PD, Wilson D, Hoskinson R, Poshkus M, Clarke JG. Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison. J Subst Abuse Treat. 2018 02; 85:45-48.
    View in: PubMed
    Score: 0.307
  29. Friedmann PD, Andrews CM, Humphreys K. How ACA Repeal Would Worsen the Opioid Epidemic. N Engl J Med. 2017 Mar 09; 376(10):e16.
    View in: PubMed
    Score: 0.304
  30. Friedmann PD, Wilson D, Nunes EV, Hoskinson R, Lee JD, Gordon M, Murphy SM, Bonnie RJ, Chen DT, Boney TY, O'Brien CP. Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder? J Subst Abuse Treat. 2018 02; 85:61-65.
    View in: PubMed
    Score: 0.303
  31. Grogan CM, Andrews C, Abraham A, Humphreys K, Pollack HA, Smith BT, Friedmann PD. Survey Highlights Differences In Medicaid Coverage For Substance Use Treatment And Opioid Use Disorder Medications. Health Aff (Millwood). 2016 12 01; 35(12):2289-2296.
    View in: PubMed
    Score: 0.299
  32. Friedmann PD, Wilson D, Knudsen HK, Ducharme LJ, Welsh WN, Frisman L, Knight K, Lin HJ, James A, Albizu-Garcia CE, Pankow J, Hall EA, Urbine TF, Abdel-Salam S, Duvall JL, Vocci FJ. Effect of an organizational linkage intervention on staff perceptions of medication-assisted treatment and referral intentions in community corrections. J Subst Abuse Treat. 2015 Mar; 50:50-8.
    View in: PubMed
    Score: 0.258
  33. Andrews CM, D'Aunno TA, Pollack HA, Friedmann PD. Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs. Med Care Res Rev. 2014 Feb; 71(1):43-60.
    View in: PubMed
    Score: 0.239
  34. D'Aunno T, Pollack HA, Jiang L, Metsch LR, Friedmann PD. HIV testing in the nation's opioid treatment programs, 2005-2011: the role of state regulations. Health Serv Res. 2014 Feb; 49(1):230-48.
    View in: PubMed
    Score: 0.236
  35. Friedmann PD, Schwartz RP. Just call it "treatment". Addict Sci Clin Pract. 2012 Jun 09; 7:10.
    View in: PubMed
    Score: 0.219
  36. Friedmann PD, Jiang L, Alexander JA. Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs. J Behav Health Serv Res. 2010 Jul; 37(3):322-37.
    View in: PubMed
    Score: 0.175
  37. Stein MD, Friedmann PD. Optimizing opioid detoxification: rearranging deck chairs on the Titanic. J Addict Dis. 2007; 26(2):1-2.
    View in: PubMed
    Score: 0.150
  38. Stopka TJ, Rottapel RE, Ruggiro M, Santelices C, Friedmann PD, Pivovarova E, Evans EA. "So what's gonna happen when I get out of here?" Qualitative barriers and facilitators to MOUD continuity post-release from jail. Drug Alcohol Depend. 2026 Aug 01; 285:113227.
    View in: PubMed
    Score: 0.144
  39. Fredericksen RJ, Sibley A, Lancaster KE, Jenkins W, Mixson LS, Whitney BM, Ouellet L, Friedmann PD, Korthuis T, Delaney JAC, Tsui JI, Crane HM, Zule W, Young AM, Seal DW, Stopka TJ. Transitions from first drug use to illicit opioid and injection drug use in a multisite rural U.S. cohort of people who use drugs. Harm Reduct J. 2026 05 02; 23(1).
    View in: PubMed
    Score: 0.143
  40. Pivovarova E, Friedmann PD, Ferguson W, Bovell Ammon BJ, Stopka TJ, Evans EA. Perceived impacts of medications for opioid use disorder implementation on mental health services and substance use counseling in carceral settings: qualitative findings from 13 Massachusetts jails. Addict Sci Clin Pract. 2025 12 22; 21(1):11.
    View in: PubMed
    Score: 0.140
  41. Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005 Nov; 20(11):1038-41.
    View in: PubMed
    Score: 0.138
  42. Rottapel RE, Stopka TJ, Friedmann PD, Hoskinson RA, Englander D, Calhoun N, Senst T, Gudas C, Koutoujian PJ, Farabee D. A protocol for a randomized comparison of extended-release versus sublingual buprenorphine among pre-trial detainees in jail. Addict Sci Clin Pract. 2025 10 27; 20(1):88.
    View in: PubMed
    Score: 0.138
  43. Ober AJ, Murray-Krezan C, Page K, Friedmann PD, Anderson J, Osilla KC, Ryzewicz S, Huerta S, Mazer MW, Hoskinson RA, Garvey R, Peltz A, Watkins KE, Nuckols T, IsHak WW, Mariano LT, Danovitch I. Hospital Addiction Consultation Service and Opioid Use Disorder Treatment: The START Randomized Clinical Trial. JAMA Intern Med. 2025 06 01; 185(6):624-633.
    View in: PubMed
    Score: 0.135
  44. Rich JD, Boutwell AE, Shield DC, Key RG, McKenzie M, Clarke JG, Friedmann PD. Attitudes and practices regarding the use of methadone in US state and federal prisons. J Urban Health. 2005 Sep; 82(3):411-9.
    View in: PubMed
    Score: 0.134
  45. Mixson LS, Venkataraman A, Drumright LN, Whitney BM, Jenkins WD, Friedmann PD, Zule WA, Havens J, Ruderman SA, Stopka TJ, Korthuis PT, Pho MT, Westergaard RP, Seal DW, Go VF, Miller WC, Feinberg J, Smith G, Tsui JI, Delaney JA, Crane HM. Benzodiazepines and Opioid co-use Among Rural People Who Use Drugs: Findings From the Rural Opioid Initiative. Subst Use Addctn J. 2025 10; 46(4):847-858.
    View in: PubMed
    Score: 0.134
  46. Morenz AM, Nance RM, Mixson LS, Feinberg J, Smith G, Korthuis PT, Pho MT, Jenkins WD, Friedmann PD, Stopka TJ, Fanucchi LC, Miller WC, Go VF, Westergaard R, Seal DW, Zule WA, Crane HM, Delaney JA, Tsui JI. Barriers to accessing medications for opioid use disorder among rural individuals. Int J Drug Policy. 2025 06; 140:104805.
    View in: PubMed
    Score: 0.133
  47. Flanagan Balawajder E, Ducharme L, Taylor BG, Lamuda PA, Kolak M, Friedmann PD, Pollack HA, Schneider JA. Barriers to Universal Availability of Medications for Opioid Use Disorder in US Jails. JAMA Netw Open. 2025 04 01; 8(4):e255340.
    View in: PubMed
    Score: 0.133
  48. Pivovarova E, Planas Garcia BY, Friedmann PD, Stopka TJ, Santelices C, Evans EA. Collaborating With Jails to Provide Community-based Medication for Opioid Use Disorder: Qualitative Perspectives From MOUD Treatment Providers. J Addict Med. 2025 Jan-Feb 01; 19(1):95-101.
    View in: PubMed
    Score: 0.130
  49. Stopka TJ, Rottapel R, Friedmann PD, Pivovarova E, Evans EA. Perceptions of extended-release buprenorphine among people who received medication for opioid use disorder in jail: a qualitative study. Addict Sci Clin Pract. 2024 09 12; 19(1):68.
    View in: PubMed
    Score: 0.128
  50. Flanagan Balawajder E, Ducharme L, Taylor BG, Lamuda PA, Kolak M, Friedmann PD, Pollack HA, Schneider JA. Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails. JAMA Netw Open. 2024 09 03; 7(9):e2434704.
    View in: PubMed
    Score: 0.128
  51. Soares WE, Schoenfeld E, Friedmann PD. Precipitated Withdrawal in the Era of Street Fentanyl-The Important Thing Is to Not Stop Questioning. JAMA Netw Open. 2024 09 03; 7(9):e2435857.
    View in: PubMed
    Score: 0.128
  52. Williams AR, Mauro CM, Chiodo L, Huber B, Cruz A, Crystal S, Samples H, Nowels M, Wilson A, Friedmann PD, Remien RH, Olfson M. Buprenorphine treatment and clinical outcomes under the opioid use disorder cascade of care. Drug Alcohol Depend. 2024 Oct 01; 263:112389.
    View in: PubMed
    Score: 0.127
  53. Fredericksen RJ, Mixson LS, Estadt AT, Leichtling G, Bresett J, Zule W, Walters SM, Friedmann PD, Romo E, Whitney BM, Delaney JAC, Crane HM, Tsui JI, Young A, Seal D, Stopka TJ. Barriers to retention in inpatient and residential drug treatment among persons who use opioids and/or injection drugs living in the rural U.S. J Subst Use Addict Treat. 2024 Oct; 165:209453.
    View in: PubMed
    Score: 0.127
  54. Bovell-Ammon BJ, Yan S, Dunn D, Evans EA, Friedmann PD, Walley AY, LaRochelle MR. Receipt of medications for opioid use disorder before and after incarceration in Massachusetts State prisons, 2014-2019. Drug Alcohol Depend. 2024 Sep 01; 262:111392.
    View in: PubMed
    Score: 0.127
  55. Evans SK, Ober AJ, Korn AR, Peltz A, Friedmann PD, Page K, Murray-Krezan C, Huerta S, Ryzewicz SJ, Tarhuni L, Nuckols TK, E Watkins K, Danovitch I. Contextual barriers and enablers to establishing an addiction-focused consultation team for hospitalized adults with opioid use disorder. Addict Sci Clin Pract. 2024 04 26; 19(1):31.
    View in: PubMed
    Score: 0.125
  56. Sibley AL, Klein E, Cooper HLF, Livingston MD, Baker R, Walters SM, Gicquelais RE, Ruderman SA, Friedmann PD, Jenkins WD, Go VF, Miller WC, Westergaard RP, Crane HM. The relationship between felt stigma and non-fatal overdose among rural people who use drugs. Harm Reduct J. 2024 04 06; 21(1):77.
    View in: PubMed
    Score: 0.124
  57. Bovell-Ammon BJ, Yan S, Dunn D, Evans EA, Friedmann PD, Walley AY, LaRochelle MR. Prison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes. JAMA Netw Open. 2024 03 04; 7(3):e242732.
    View in: PubMed
    Score: 0.123
  58. Stopka TJ, Estadt AT, Leichtling G, Schleicher JC, Mixson LS, Bresett J, Romo E, Dowd P, Walters SM, Young AM, Zule W, Friedmann PD, Go VF, Baker R, Fredericksen RJ. Barriers to opioid use disorder treatment among people who use drugs in the rural United States: A qualitative, multi-site study. Soc Sci Med. 2024 04; 346:116660.
    View in: PubMed
    Score: 0.123
  59. Rains A, Sibley AL, Levander XA, Walters SM, Nolte K, Colston DC, Piscalko HM, Go VF, Friedmann PD, Seal DW. "I would do anything but that": Attitudes towards sex work among rural people who use drugs. Int J Drug Policy. 2023 12; 122:104237.
    View in: PubMed
    Score: 0.120
  60. Tsui JI, Whitney BM, Korthuis PT, Chan B, Pho MT, Jenkins WD, Young AM, Cooper HLF, Friedmann PD, Stopka TJ, de Gijsel D, Miller WC, Go VF, Westergaard R, Brown R, Seal DW, Zule WA, Feinberg J, Smith GS, Mixson LS, Fredericksen R, Crane HM, Delaney JA. Methamphetamine use and utilization of medications for opioid use disorder among rural people who use drugs. Drug Alcohol Depend. 2023 09 01; 250:110911.
    View in: PubMed
    Score: 0.118
  61. Church B, Clark R, Mohn W, Potee R, Friedmann P, Soares WE. Methadone Induction for a Patient With Precipitated Withdrawal in the Emergency Department: A Case Report. J Addict Med. 2023 May-Jun 01; 17(3):367-370.
    View in: PubMed
    Score: 0.114
  62. Stopka TJ, Rottapel RE, Ferguson WJ, Pivovarova E, Toro-Mejias LD, Friedmann PD, Evans EA. Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers. Int J Drug Policy. 2022 Dec; 110:103803.
    View in: PubMed
    Score: 0.111
  63. Ober AJ, Murray-Krezan C, Page K, Friedmann PD, Chan Osilla K, Ryzewicz S, Huerta S, Mazer MW, Leamon I, Messineo G, Watkins KE, Nuckols T, Danovitch I. The Substance Use Treatment and Recovery Team (START) study: protocol for a multi-site randomized controlled trial evaluating an intervention to improve initiation of medication and linkage to post-discharge care for hospitalized patients with opioid use disorder. Addict Sci Clin Pract. 2022 07 28; 17(1):39.
    View in: PubMed
    Score: 0.110
  64. Jenkins RA, Whitney BM, Nance RM, Allen TM, Cooper HLF, Feinberg J, Fredericksen R, Friedmann PD, Go VF, Jenkins WD, Korthuis PT, Miller WC, Pho MT, Rudolph AE, Seal DW, Smith GS, Stopka TJ, Westergaard RP, Young AM, Zule WA, Delaney JAC, Tsui JI, Crane HM. The Rural Opioid Initiative Consortium description: providing evidence to Understand the Fourth Wave of the Opioid Crisis. Addict Sci Clin Pract. 2022 07 26; 17(1):38.
    View in: PubMed
    Score: 0.110
  65. McGarry KA, Stein MD, Clarke JG, Friedmann PD. Utilization of preventive health services by HIV-seronegative injection drug users. J Addict Dis. 2002; 21(2):93-102.
    View in: PubMed
    Score: 0.106
  66. Evans EA, Stopka TJ, Pivovarova E, Murphy SM, Taxman FS, Ferguson WJ, Bernson D, Santelices C, McCollister KE, Hoskinson R, Lincoln T, Friedmann PD. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN). J Subst Abuse Treat. 2021 09; 128:108275.
    View in: PubMed
    Score: 0.099
  67. Nolte K, Drew AL, Friedmann PD, Romo E, Kinney LM, Stopka TJ. Opioid initiation and injection transition in rural northern New England: A mixed-methods approach. Drug Alcohol Depend. 2020 12 01; 217:108256.
    View in: PubMed
    Score: 0.097
  68. Peacock-Chambers E, Leyenaar JK, Foss S, Feinberg E, Wilson D, Friedmann PD, Visintainer P, Singh R. Early Intervention Referral and Enrollment Among Infants with Neonatal Abstinence Syndrome. J Dev Behav Pediatr. 2019 Jul/Aug; 40(6):441-450.
    View in: PubMed
    Score: 0.089
  69. Abraham AJ, Smith BT, Andrews CM, Bersamira CS, Grogan CM, Pollack HA, Friedmann PD. Changes in State Technical Assistance Priorities and Block Grant Funds for Addiction After ACA Implementation. Am J Public Health. 2019 06; 109(6):885-891.
    View in: PubMed
    Score: 0.088
  70. Williams AR, Nunes EV, Bisaga A, Pincus HA, Johnson KA, Campbell AN, Remien RH, Crystal S, Friedmann PD, Levin FR, Olfson M. Developing an opioid use disorder treatment cascade: A review of quality measures. J Subst Abuse Treat. 2018 08; 91:57-68.
    View in: PubMed
    Score: 0.083
  71. Chen DT, Ko TM, Allen AA, Bonnie RJ, Suratt CE, Appelbaum PS, Nunes EV, Friedmann PD, Lee JD, Gordon MS, McDonald R, Wilson D, Boney TY, Murphy SM, O'Brien CP. Personal Control Over Decisions to Participate in Research by Persons With Histories of Both Substance Use Disorders and Criminal Justice Supervision. J Empir Res Hum Res Ethics. 2018 04; 13(2):160-172.
    View in: PubMed
    Score: 0.081
  72. Allen AA, Chen DT, Bonnie RJ, Ko TM, Suratt CE, Lee JD, Friedmann PD, Gordon M, McDonald R, Murphy SM, Boney TY, Nunes EV, O'Brien CP. Assessing informed consent in an opioid relapse prevention study with adults under current or recent criminal justice supervision. J Subst Abuse Treat. 2017 10; 81:66-72.
    View in: PubMed
    Score: 0.078
  73. Nunes EV, Gordon M, Friedmann PD, Fishman MJ, Lee JD, Chen DT, Hu MC, Boney TY, Wilson D, O'Brien CP. Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone. J Subst Abuse Treat. 2018 02; 85:49-55.
    View in: PubMed
    Score: 0.077
  74. Murphy SM, Polsky D, Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Bonnie RJ, Gordon M, Chen DT, Boney TY, O'Brien CP. Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder. Addiction. 2017 Aug; 112(8):1440-1450.
    View in: PubMed
    Score: 0.077
  75. Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA, Wilson D, McDonald R, Rotrosen J, Gourevitch MN, Gordon M, Fishman M, Chen DT, Bonnie RJ, Cornish JW, Murphy SM, O'Brien CP. Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. N Engl J Med. 2016 Mar 31; 374(13):1232-42.
    View in: PubMed
    Score: 0.071
  76. Mitchell SG, Willet J, Monico LB, James A, Rudes DS, Viglione J, Schwartz RP, Gordon MS, Friedmann PD. Community correctional agents' views of medication-assisted treatment: Examining their influence on treatment referrals and community supervision practices. Subst Abus. 2016; 37(1):127-33.
    View in: PubMed
    Score: 0.070
  77. Lee JD, Friedmann PD, Boney TY, Hoskinson RA, McDonald R, Gordon M, Fishman M, Chen DT, Bonnie RJ, Kinlock TW, Nunes EV, Cornish JW, O'Brien CP. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial. Contemp Clin Trials. 2015 Mar; 41:110-7.
    View in: PubMed
    Score: 0.066
  78. Green TC, Mann MR, Bowman SE, Zaller N, Soto X, Gadea J, Cordy C, Kelly P, Friedmann PD. How does use of a prescription monitoring program change pharmacy practice? J Am Pharm Assoc (2003). 2013 May-Jun; 53(3):273-81.
    View in: PubMed
    Score: 0.058
  79. Zaller N, McKenzie M, Friedmann PD, Green TC, McGowan S, Rich JD. Initiation of buprenorphine during incarceration and retention in treatment upon release. J Subst Abuse Treat. 2013 Aug; 45(2):222-6.
    View in: PubMed
    Score: 0.058
  80. Taylor LE, Maynard MA, Friedmann PD, Macleod CJ, Rich JD, Flanigan TP, Sylvestre DL. Buprenorphine for human immunodeficiency virus/hepatitis C virus-coinfected patients: does it serve as a bridge to hepatitis C virus therapy? J Addict Med. 2012 Sep; 6(3):179-85.
    View in: PubMed
    Score: 0.056
  81. McKenzie M, Zaller N, Dickman SL, Green TC, Parihk A, Friedmann PD, Rich JD. A randomized trial of methadone initiation prior to release from incarceration. Subst Abus. 2012; 33(1):19-29.
    View in: PubMed
    Score: 0.053
  82. Coviello DM, Cornish JW, Lynch KG, Boney TY, Clark CA, Lee JD, Friedmann PD, Nunes EV, Kinlock TW, Gordon MS, Schwartz RP, Nuwayser ES, O'Brien CP. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Subst Abus. 2012; 33(1):48-59.
    View in: PubMed
    Score: 0.053
  83. Cioe PA, Friedmann PD, Stein MD. Erectile dysfunction in opioid users: lack of association with serum testosterone. J Addict Dis. 2010 Oct; 29(4):455-60.
    View in: PubMed
    Score: 0.049
  84. Stein MD, Herman DS, Kettavong M, Cioe PA, Friedmann PD, Tellioglu T, Anderson BJ. Antidepressant treatment does not improve buprenorphine retention among opioid-dependent persons. J Subst Abuse Treat. 2010 Sep; 39(2):157-66.
    View in: PubMed
    Score: 0.048
  85. Estadt AT, Kline D, Miller WC, Feinberg J, Hurt CB, Mixson LS, Friedmann PD, Lowe K, Tsui JI, Young AM, Cooper H, Korthuis PT, Pho MT, Jenkins W, Westergaard RP, Go VF, Brook D, Smith G, Rice DR, Lancaster KE. Differences in hepatitis C virus (HCV) testing and treatment by opioid, stimulant, and polysubstance use among people who use drugs in rural U.S. communities. Harm Reduct J. 2024 11 29; 21(1):214.
    View in: PubMed
    Score: 0.032
  86. Ballard AM, Kesich Z, Crane HM, Feinberg J, Friedmann PD, Go VF, Jenkins WD, Korthuis PT, Miller WC, Pho MT, Seal DW, Smith GS, Stopka TJ, Westergaard RP, Zule WA, Young AM, Cooper HL. Rural houselessness among people who use drugs in the United States: Results from the National Rural Opioid Initiative. Drug Alcohol Depend. 2025 Jan 01; 266:112498.
    View in: PubMed
    Score: 0.032
  87. Prusaczyk B, Tilmon S, Landman J, Seibert D, Colston DC, Westergaard R, Cooper H, Feinberg J, Friedmann PD, Go VF, Khoury D, Korthius T, Mixson S, Moellner A, Nolte K, Smith G, Young A, Pho MT, Jenkins W. Barriers to Healthcare and Social Service Utilization Among Rural Older Adults Who Use Drugs. J Appl Gerontol. 2024 12; 43(12):1977-1984.
    View in: PubMed
    Score: 0.031
  88. Rudolph AE, Nance RM, Bobashev G, Brook D, Akhtar W, Cook R, Cooper HL, Friedmann PD, Frost SDW, Go VF, Jenkins WD, Korthuis PT, Miller WC, Pho MT, Ruderman SA, Seal DW, Stopka TJ, Westergaard RP, Young AM, Zule WA, Tsui JI, Crane HM, Whitney BM, Delaney JAC. Evaluation of respondent-driven sampling in seven studies of people who use drugs from rural populations: findings from the Rural Opioid Initiative. BMC Med Res Methodol. 2024 04 23; 24(1):94.
    View in: PubMed
    Score: 0.031
  89. Estadt AT, Miller WC, Kline D, Whitney BM, Young AM, Todd Korthuis P, Stopka TJ, Feinberg J, Zule WA, Pho MT, Friedmann PD, Westergaard RP, Eagen KV, Seaman A, Ma J, Go VF, Lancaster KE. Associations of hepatitis C virus (HCV) antibody positivity with opioid, stimulant, and polysubstance injection among people who inject drugs (PWID) in rural U.S. communities. Int J Drug Policy. 2025 07; 141:104222.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.